1
|
Chen JK, Kuo CH, Kuo WW, Day CH, Wang TF, Ho TJ, Lin PY, Lin SZ, Shih TC, Shih CY, Huang CY, Lu CY. Artemisia argyi extract ameliorates IL-17A-induced inflammatory response by regulation of NF-κB and Nrf2 expression in HIG-82 synoviocytes. ENVIRONMENTAL TOXICOLOGY 2022; 37:2793-2803. [PMID: 35959841 DOI: 10.1002/tox.23637] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/23/2022] [Revised: 07/16/2022] [Accepted: 07/31/2022] [Indexed: 06/15/2023]
Abstract
Rheumatoid arthritis (RA) is an autoimmune and chronic inflammatory disease that results in joint destruction and disability in the adult population. RA is characterized by the accumulation and proliferation of fibroblast-like synoviocytes. Many pro-inflammatory mediators are associated with RA, such as interleukin (IL)-1β, IL-6, IL-17, cyclooxygenase-2 (COX-2), and nuclear factor kappa B (NF-κB). Furthermore, IL-17 upregulates the production of other pro-inflammatory mediators, including IL-1β and IL-6, and promotes the recruitment of neutrophils in RA. Artemisia argyi, a traditional Chinese herbal medicine, is used for the treatment of diseases associated with inflammation and microbial infections. In this study, synoviocytes (HIG-82) were treated with varying doses of A. argyi extract (AAE) following IL-17A stimulation. Proliferation of the IL-17A-stimulated cells was increased compared to that of the non-stimulated control cells. However, cell proliferation decreased significantly in a dose-dependent manner following AAE treatment. Treatment of IL-17A-stimulated cells with AAE resulted in decreased levels of phosphorylated (p)-NF-κB, p-IκB-α, and COX-2. Enzyme-linked immunosorbent assay results showed that IL-1β and IL-6 levels were increased in the IL-17A-stimulated group but decreased in the AAE treatment group. Additionally, we found that AAE facilitated nuclear factor erythroid 2-related factor 2 (Nrf2) expression and promoted its nuclear translocation, thereby inducing the expression of heme oxygenase-1. Moreover, AAE did not attenuate IL-17A-induced inflammatory mediator production in the presence of ML385, an Nrf2-specific inhibitor. These results suggest that the downregulation of expression of pro-inflammatory cytokines and the transcription factor NF-κB by AAE may be a potential therapeutic strategy for reducing inflammation associated with RA.
Collapse
Affiliation(s)
- Jhong-Kuei Chen
- Integration of Chinese Medicine and Modern Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan
- Department of Chinese Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan
- School of Post-Baccalaureate Chinese Medicine, Tzu Chi University, Hualien, Taiwan
| | - Chia-Hua Kuo
- Department of Sports Sciences, University of Taipei, Taipei, Taiwan
| | - Wei-Wen Kuo
- Department of Biological Science and Technology, China Medical University, Taichung, Taiwan
- Biotechnology Industry, China Medical University, Taichung, Taiwan
| | | | - Tso-Fu Wang
- Department of Hematology and Oncology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan
- Department of Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Tzu Chi University, Hualien, Taiwan
| | - Tsung-Jung Ho
- Integration of Chinese Medicine and Modern Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan
- Department of Chinese Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan
- School of Post-Baccalaureate Chinese Medicine, Tzu Chi University, Hualien, Taiwan
| | - Pi-Yu Lin
- Buddhist Tzu Chi Charity Foundation, Hualien, Taiwan
| | - Shinn-Zong Lin
- Bioinnovation Center, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan
- Department of Neurosurgery, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan
| | - Tzu-Ching Shih
- Department of Biomedical Imaging and Radiological Science, College of Medicine, China Medical University, Taichung, Taiwan
| | | | - Chih-Yang Huang
- Cardiovascular and Mitochondrial Related Disease Research Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan
- Department of Biological Science and Technology, Asia University, Taichung, Taiwan
- Center of General Education, Buddhist Tzu Chi Medical Foundation, Tzu Chi University of Science and Technology, Hualien, Taiwan
- Department of Medical Research, China Medical University Hospital, China Medical University, Taichung, Taiwan
| | - Cheng-You Lu
- Cardiovascular and Mitochondrial Related Disease Research Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan
- Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan
| |
Collapse
|
2
|
Shen P, Jiao Y, Miao L, Chen J, Momtazi‐Borojeni AA. Immunomodulatory effects of berberine on the inflamed joint reveal new therapeutic targets for rheumatoid arthritis management. J Cell Mol Med 2020; 24:12234-12245. [PMID: 32969153 PMCID: PMC7687014 DOI: 10.1111/jcmm.15803] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2020] [Revised: 07/21/2020] [Accepted: 07/30/2020] [Indexed: 12/13/2022] Open
Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory syndrome designated by synovial joint inflammation leading to cartilage degradation and bone damage as well as progressive disability. Synovial inflammation is promoted through the infiltration of mononuclear immune cells, dominated by CD4+ T cells, macrophages and dendritic cells (DCs), together with fibroblast-like synoviocytes (FLS), into the synovial compartment. Berberine is a bioactive isoquinoline alkaloid compound showing various pharmacological properties that are mainly attributed to immunomodulatory and anti-inflammatory effects. Several lines of experimental study have recently investigated the therapeutic potential of berberine and its underlying mechanisms in treating RA condition. The present review aimed to clarify determinant cellular and molecular targets of berberine in RA and found that berberine through modulating several signalling pathways involved in the joint inflammation, including PI3K/Akt, Wnt1/β-catenin, AMPK/lipogenesis and LPA/LPA1 /ERK/p38 MAPK can inhibit inflammatory proliferation of FLS cells, suppress DC activation and modulate Th17/Treg balance and thus prevent cartilage and bone destruction. Importantly, these molecular targets may explore new therapeutic targets for RA treatment.
Collapse
Affiliation(s)
- Peng Shen
- Department of StomatologyClinical Department of Aerospace CityNorthern Beijing Medical DistrictChinese PLA General HospitalBeijingChina
| | - Yang Jiao
- Department of StomatologyThe 7th Medical CenterChinese PLA General HospitalBeijingChina
- Outpatient Department of PLA Macao GarrisonMacaoChina
| | - Li Miao
- Department of StomatologyThe 7th Medical CenterChinese PLA General HospitalBeijingChina
| | - Ji‐hua Chen
- National Clinical Research Center for Oral Diseases & State Key Laboratory of Military Stomatology & Shaanxi Key Laboratory of Oral DiseasesDepartment of ProsthodonticsSchool of StomatologyThe Fourth Military Medical UniversityXi'anChina
| | | |
Collapse
|
3
|
Cascão R, Vidal B, Carvalho T, Lopes IP, Romão VC, Goncalves J, Moita LF, Fonseca JE. Celastrol Efficacy by Oral Administration in the Adjuvant-Induced Arthritis Model. Front Med (Lausanne) 2020; 7:455. [PMID: 33015082 PMCID: PMC7505947 DOI: 10.3389/fmed.2020.00455] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2019] [Accepted: 07/08/2020] [Indexed: 12/13/2022] Open
Abstract
Background: We previously demonstrated that celastrol has significant anti-inflammatory and bone protective effects when administered via the intraperitoneal route. For further preclinical evaluation, an effective oral administration of celastrol is crucial. Here we aimed to study the therapeutic dose range for its oral administration. Methods: Celastrol (1–25 μg/g/day, N = 5/group) was administrated orally to female adjuvant-induced arthritis (AIA) rats after 8 days of disease induction for a period of 14 days. A group of healthy (N = 8) and arthritic (N = 15) gender- and age-matched Wistar rats was used as controls. During the treatment period, the inflammatory score, ankle perimeter, and body weight were measured. At the end of the treatment, the animals were sacrificed, blood was collected for clinical pathology, necropsy was performed with collection of internal organs for histopathological analysis, and paw samples were used for disease scoring. Results: Doses higher than 2.5 μg/g/day of celastrol reduced the inflammatory score and ankle swelling, preserved joint structure, halted bone destruction, and diminished the number of synovial CD68+ macrophages. Bone resorption and turnover were also reduced at 5 and 7.5 μg/g/day doses. However, the dose of 7.5 μg/g/day was associated with thymic and liver lesions, and higher doses showed severe toxicity. Conclusion: Oral administration of celastrol above 2.5 μg/g/day ameliorates arthritis. This data supports and gives relevant information for the development of a preclinical test of celastrol in the setting of a chronic model of arthritis since rheumatoid arthritis is a long-term disease.
Collapse
Affiliation(s)
- Rita Cascão
- Unidade de Investigação em Reumatologia, Faculdade de Medicina, Instituto de Medicina Molecular-João Lobo Antunes, Centro Académico de Medicina de Lisboa, Universidade de Lisboa, Lisbon, Portugal
| | - Bruno Vidal
- Unidade de Investigação em Reumatologia, Faculdade de Medicina, Instituto de Medicina Molecular-João Lobo Antunes, Centro Académico de Medicina de Lisboa, Universidade de Lisboa, Lisbon, Portugal
| | - Tânia Carvalho
- Comparative Pathology Unit, Instituto de Medicina Molecular-João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
| | - Inês Pascoal Lopes
- Unidade de Investigação em Reumatologia, Faculdade de Medicina, Instituto de Medicina Molecular-João Lobo Antunes, Centro Académico de Medicina de Lisboa, Universidade de Lisboa, Lisbon, Portugal
| | - Vasco C Romão
- Unidade de Investigação em Reumatologia, Faculdade de Medicina, Instituto de Medicina Molecular-João Lobo Antunes, Centro Académico de Medicina de Lisboa, Universidade de Lisboa, Lisbon, Portugal.,Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
| | - João Goncalves
- Faculdade de Farmácia, iMed - Research Institute of Medicines, Universidade de Lisboa, Lisbon, Portugal
| | - Luis Ferreira Moita
- Innate Immunity and Inflammation Laboratory, Instituto Gulbenkian de Ciência, Oeiras, Portugal
| | - João Eurico Fonseca
- Unidade de Investigação em Reumatologia, Faculdade de Medicina, Instituto de Medicina Molecular-João Lobo Antunes, Centro Académico de Medicina de Lisboa, Universidade de Lisboa, Lisbon, Portugal.,Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
| |
Collapse
|
4
|
Rivellese F, Rossi FW, Giorli G, Napolitano F, de Paulis A, Pitzalis C. Persistence of Mast Cell-Positive Synovitis in Early Rheumatoid Arthritis Following Treatment With Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs. Front Pharmacol 2020; 11:1051. [PMID: 32760275 PMCID: PMC7371927 DOI: 10.3389/fphar.2020.01051] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2020] [Accepted: 06/29/2020] [Indexed: 11/13/2022] Open
Abstract
Mast cells (MCs) are immune cells infiltrating the synovial membrane and implicated in the pathogenesis of Rheumatoid Arthritis (RA). Their infiltration in the synovia of early RA patients has been shown to be associated with systemic inflammation, disease activity and autoantibody positivity. Here, we analyzed their presence in matched synovial samples obtained by ultrasound-guided synovial biopsies pre- and post-treatment with conventional synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs) (n=20). Upon IHC staining, patients were classified as MC+ve/-ve based on the presence/absence of CD117+ synovial MCs. At baseline, MC+ve patients had significantly higher synovial inflammation, inflammatory markers, disease activity and a higher prevalence of lympho-myeloid aggregates. Synovial biopsies after 6 months of treatment with csDMARDs showed a significant reduction of synovitis scores, but only a partial reduction of MC numbers. Accordingly, 45% of patients (9/20) were MC+ve after treatment, in association with significantly higher degree of synovitis and higher proportion lympho-myeloid aggregates. Finally, significantly lower patients with MC+ve synovitis at 6 months reached Low Disease Activity (LDA), while the association of MCs with disease activity was independent from lymphoid aggregates, after adjustment for BMI and age. Overall, this study confirms the relevance of MCs as part of the inflammatory infiltrate in the synovia of RA patients, warranting further investigations in larger cohorts to clarify their role in disease progression and response to treatment and their relevance as prognostic markers and potential therapeutic targets.
Collapse
Affiliation(s)
- Felice Rivellese
- Centre for Experimental Medicine & Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
| | - Francesca W. Rossi
- Department of Translational Medical Sciences (DiSMeT) and Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy
| | - Giovanni Giorli
- Centre for Experimental Medicine & Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
| | - Filomena Napolitano
- Department of Translational Medical Sciences (DiSMeT) and Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy
| | - Amato de Paulis
- Department of Translational Medical Sciences (DiSMeT) and Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, Naples, Italy
| | - Costantino Pitzalis
- Centre for Experimental Medicine & Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
| |
Collapse
|
5
|
Berberine attenuates arthritis in adjuvant-induced arthritic rats associated with regulating polarization of macrophages through AMPK/NF-кB pathway. Eur J Pharmacol 2019; 852:179-188. [DOI: 10.1016/j.ejphar.2019.02.036] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2018] [Revised: 02/20/2019] [Accepted: 02/20/2019] [Indexed: 01/22/2023]
|
6
|
Kubota A, Suguro T, Nakajima A, Sonobe M, Tsuchiya K. Effect of biological agents on synovial tissues from patients with rheumatoid arthritis. Mod Rheumatol 2019; 30:282-286. [PMID: 30786801 DOI: 10.1080/14397595.2019.1583783] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Objectives: To compare the inflammation of synovium before and after biological agents in the patients with rheumatoid arthritis (RA) and to investigate the association between synovial histopathology and disease activity.Methods: Synovial tissues were obtained during operations from 34 patients before and after treatment with biological agents. The synovial tissue was evaluated using hematoxylin and eosin staining. Synovial histopathology was evaluated by Rooney score.Results: The Rooney score was also significantly decreased after treatment with biological agents in all items (p < .001). After the treatment with biological agents, Moderate disease activity group had significantly higher scores of focal aggregates of lymphocytes (p = .02), diffuse infiltrates of lymphocytes (p = .019), and the Rooney total scores (p = .002) than remission and low disease activity groups.Conclusion: Our results demonstrated that biological agents significantly decreased the RA synovial inflammation and synovial histopathology in sublining layer reflected disease activity.
Collapse
Affiliation(s)
- Ayako Kubota
- Department of Orthopaedic Surgery, Toho University Omori Medical Center, Tokyo, Japan
| | - Toru Suguro
- Department of Orthopaedic Surgery, Toho University Omori Medical Center, Tokyo, Japan
| | - Arata Nakajima
- Departments of Orthopaedics and Rheumatology, Toho University Sakura Medical Center, Chiba, Japan
| | - Masato Sonobe
- Departments of Orthopaedics and Rheumatology, Toho University Sakura Medical Center, Chiba, Japan
| | - Kazuaki Tsuchiya
- Department of Orthopaedic Surgery, Toho University Omori Medical Center, Tokyo, Japan
| |
Collapse
|
7
|
Serum metabolomic profiling predicts synovial gene expression in rheumatoid arthritis. Arthritis Res Ther 2018; 20:164. [PMID: 30075744 PMCID: PMC6091066 DOI: 10.1186/s13075-018-1655-3] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2018] [Accepted: 06/29/2018] [Indexed: 12/18/2022] Open
Abstract
Background Metabolomics is an emerging field of biomedical research that may offer a better understanding of the mechanisms of underlying conditions including inflammatory arthritis. Perturbations caused by inflamed synovial tissue can lead to correlated changes in concentrations of certain metabolites in the synovium and thereby function as potential biomarkers in blood. Here, we explore the hypothesis of whether characterization of patients’ metabolomic profiles in blood, utilizing 1H-nuclear magnetic resonance (NMR), predicts synovial marker profiling in rheumatoid arthritis (RA). Methods Nineteen active, seropositive patients with RA, on concomitant methotrexate, were studied. One of the involved joints was a knee or a wrist appropriate for arthroscopy. A Bruker Avance 700 MHz spectrometer was used to acquire NMR spectra of serum samples. Gene expression in synovial tissue obtained by arthroscopy was analyzed by real-time PCR. Data processing and statistical analysis were performed in Python and SPSS. Results Analysis of the relationships between each synovial marker-metabolite pair using linear regression and controlling for age and gender revealed significant clustering within the data. We observed an association of serine/glycine/phenylalanine metabolism and aminoacyl-tRNA biosynthesis with lymphoid cell gene signature. Alanine/aspartate/glutamate metabolism and choline-derived metabolites correlated with TNF-α synovial expression. Circulating ketone bodies were associated with gene expression of synovial metalloproteinases. Discriminant analysis identified serum metabolites that classified patients according to their synovial marker levels. Conclusion The relationship between serum metabolite profiles and synovial biomarker profiling suggests that NMR may be a promising tool for predicting specific pathogenic pathways in the inflamed synovium of patients with RA. Electronic supplementary material The online version of this article (10.1186/s13075-018-1655-3) contains supplementary material, which is available to authorized users.
Collapse
|
8
|
Wang K, Zhang D, Liu Y, Wang X, Zhao J, Sun T, Jin T, Li B, Pathak JL. Traditional Chinese medicine formula Bi-Qi capsule alleviates rheumatoid arthritis-induced inflammation, synovial hyperplasia, and cartilage destruction in rats. Arthritis Res Ther 2018. [PMID: 29540195 PMCID: PMC5853033 DOI: 10.1186/s13075-018-1547-6] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND Traditional Chinese medicine (TCM) formula Bi-Qi capsule (Bi-Qi) is a commonly prescribed drug to treat rheumatoid arthritis (RA). However, the mechanism of Bi-Qi-mediated amelioration of RA pathogenesis is still a mystery. Collagen induced arthritis (CIA) in rats is an established model that shares many similarities with RA in humans. In this study we investigated the effect of Bi-Qi on the pathogenesis of CIA in rats. METHODS CIA was developed in Sprague-Dawley (S.D) rats (n = 60, female) and used as a model resembling RA in humans. Rats were treated with a high or moderate dose of Bi-Qi, or methotrexate (MTX). Effects of the treatment on local joint and systemic inflammation, synovial hyperplasia, cartilage destruction, and other main features in the pathogenesis of CIA were analyzed. RESULTS Inflamed and swollen ankles and joints were observed in arthritic rats, while Bi-Qi or MTX treatment alleviated these symptoms. Only the Bi-Qi moderate dose decreased RA-induced serum levels of tumor necrosis factor-alpha (TNF-α). Both Bi-Qi and MTX reduced the interleukin (IL)-18 serum level. Protein levels of cartilage oligomeric matrix protein and osteopontin in serum, synovium, and cartilage were elevated in arthritic rats, while Bi-Qi alleviated these effects. Synovial hyperplasia, inflammatory cell infiltration in synovium and a high degree of cartilage degradation was observed in RA, and Bi-Qi or MTX alleviated this effect. Bi-Qi at the moderate dose was the most effective in mitigating CIA-related clinical complications. CONCLUSIONS Our findings showed that Bi-Qi alleviates CIA-induced inflammation, synovial hyperplasia, cartilage destruction, and the other main features in the pathogenesis of CIA. This provides fundamental evidence for the anti-arthritic properties of Bi-Qi and corroborates the use of Bi-Qi TCM formula for the treatment of RA.
Collapse
Affiliation(s)
- Kai Wang
- Department of International Medicine, Geriatric Disease Research Institute, Tianjin Hospital, Tianjin, 300211, China
| | - Dongmei Zhang
- Department of Traditional Chinese Medicine, Tianjin Medical University General Hospital, Tianjin, 300070, China
| | - Yan Liu
- Department of International Medicine, Geriatric Disease Research Institute, Tianjin Hospital, Tianjin, 300211, China
| | - Xuan Wang
- Department of International Medicine, Geriatric Disease Research Institute, Tianjin Hospital, Tianjin, 300211, China
| | - Jiantong Zhao
- Department of International Medicine, Geriatric Disease Research Institute, Tianjin Hospital, Tianjin, 300211, China
| | - Tingting Sun
- Department of International Medicine, Geriatric Disease Research Institute, Tianjin Hospital, Tianjin, 300211, China
| | - Tingting Jin
- Department of International Medicine, Geriatric Disease Research Institute, Tianjin Hospital, Tianjin, 300211, China
| | - Baoli Li
- Department of Traditional Chinese Medicine, Tianjin Medical University General Hospital, Tianjin, 300070, China
| | - Janak L Pathak
- School of Pharmaceutical Science and Technology, Health Sciences Platform, Tianjin University, Tianjin, 300072, China.
| |
Collapse
|
9
|
Gao YX, Cheng BF, Lian JJ, Guo DD, Qin JW, Zhang YB, Yang HJ, Wang M, Wang L, Feng ZW. Liquiritin, a flavone compound from licorice, inhibits IL-1β-induced inflammatory responses in SW982 human synovial cells. J Funct Foods 2017. [DOI: 10.1016/j.jff.2017.03.039] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023] Open
|
10
|
Schultz HS, Guo L, Keller P, Fleetwood AJ, Sun M, Guo W, Ma C, Hamilton JA, Bjørkdahl O, Berchtold MW, Panina S. OSCAR-collagen signaling in monocytes plays a proinflammatory role and may contribute to the pathogenesis of rheumatoid arthritis. Eur J Immunol 2016; 46:952-63. [PMID: 26786702 DOI: 10.1002/eji.201545986] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2015] [Revised: 12/15/2015] [Accepted: 01/12/2016] [Indexed: 01/26/2023]
Abstract
Osteoclast-associated receptor (OSCAR) is an activating receptor expressed by human myeloid cells. Collagen type I (ColI) and collagen type II (ColII) serve as ligands for OSCAR. OSCAR-collagen interaction stimulates RANK-dependent osteoclastogenesis. We have recently reported that OSCAR promotes functional maturation of monocyte-derived dendritic cells. OSCAR is upregulated on monocytes from rheumatoid arthritis (RA) patients with active disease, and these monocytes show an increased proosteoclastogenic potential. In the current study, we have addressed a functional role for an OSCAR-collagen interaction on monocytes. We show that OSCAR-ColII signaling promoted the survival of monocytes. Moreover, ColII stimulated the release of proinflammatory cytokines by monocytes from healthy donors, which could be completely blocked by an anti-OSCAR monoclonal antibody. Mononuclear cells from the synovial fluid of RA patients plated on ColII secreted TNF-α and IL-8 in an OSCAR-dependent manner. Global RNA profiling showed that components of multiple signaling pathways relevant to RA pathogenesis are regulated at the transcriptional level by OSCAR in monocytes. Thus, OSCAR can play a proinflammatory role in monocyte-derived cells and may contribute crucially on multiple levels to RA pathogenesis.
Collapse
Affiliation(s)
- Heidi S Schultz
- Biopharmaceutical Research Unit, Novo Nordisk A/S, Måløv, Denmark.,Department of Biology, Copenhagen University, Copenhagen, Denmark
| | - Li Guo
- Novo Nordisk Research Centre China CA, Beijing, China
| | - Pernille Keller
- Biopharmaceutical Research Unit, Novo Nordisk A/S, Måløv, Denmark
| | - Andrew J Fleetwood
- Department of Medicine, The Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria, Australia
| | - Mingyi Sun
- Novo Nordisk Research Centre China CA, Beijing, China
| | - Wei Guo
- Novo Nordisk Research Centre China CA, Beijing, China
| | - Chunyan Ma
- Novo Nordisk Research Centre China CA, Beijing, China
| | - John A Hamilton
- Department of Medicine, The Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria, Australia
| | - Olle Bjørkdahl
- Biopharmaceutical Research Unit, Novo Nordisk A/S, Måløv, Denmark
| | | | - Svetlana Panina
- Biopharmaceutical Research Unit, Novo Nordisk A/S, Måløv, Denmark
| |
Collapse
|
11
|
Cascão R, Vidal B, Lopes IP, Paisana E, Rino J, Moita LF, Fonseca JE. Decrease of CD68 Synovial Macrophages in Celastrol Treated Arthritic Rats. PLoS One 2015; 10:e0142448. [PMID: 26658436 PMCID: PMC4676706 DOI: 10.1371/journal.pone.0142448] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2015] [Accepted: 10/21/2015] [Indexed: 01/08/2023] Open
Abstract
Background Rheumatoid arthritis (RA) is a chronic immune-mediated inflammatory disease characterized by cellular infiltration into the joints, hyperproliferation of synovial cells and bone damage. Available treatments for RA only induce remission in around 30% of the patients, have important adverse effects and its use is limited by their high cost. Therefore, compounds that can control arthritis, with an acceptable safety profile and low production costs are still an unmet need. We have shown, in vitro, that celastrol inhibits both IL-1β and TNF, which play an important role in RA, and, in vivo, that celastrol has significant anti-inflammatory properties. Our main goal in this work was to test the effect of celastrol in the number of sublining CD68 macrophages (a biomarker of therapeutic response for novel RA treatments) and on the overall synovial tissue cellularity and joint structure in the adjuvant-induced rat model of arthritis (AIA). Methods Celastrol was administered to AIA rats both in the early (4 days after disease induction) and late (11 days after disease induction) phases of arthritis development. The inflammatory score, ankle perimeter and body weight were evaluated during treatment period. Rats were sacrificed after 22 days of disease progression and blood, internal organs and paw samples were collected for toxicological blood parameters and serum proinflammatory cytokine quantification, as well as histopathological and immunohistochemical evaluation, respectively. Results Here we report that celastrol significantly decreases the number of sublining CD68 macrophages and the overall synovial inflammatory cellularity, and halted joint destruction without side effects. Conclusions Our results validate celastrol as a promising compound for the treatment of arthritis.
Collapse
MESH Headings
- Adjuvants, Immunologic
- Animals
- Anti-Inflammatory Agents/pharmacology
- Antigens, CD/genetics
- Antigens, CD/immunology
- Antigens, Differentiation, Myelomonocytic/genetics
- Antigens, Differentiation, Myelomonocytic/immunology
- Arthritis, Experimental/chemically induced
- Arthritis, Experimental/drug therapy
- Arthritis, Experimental/genetics
- Arthritis, Experimental/immunology
- Arthritis, Rheumatoid/drug therapy
- Arthritis, Rheumatoid/genetics
- Arthritis, Rheumatoid/immunology
- Arthritis, Rheumatoid/pathology
- Cell Count
- Female
- Gene Expression
- Humans
- Injections, Intraperitoneal
- Interleukin-1beta/genetics
- Interleukin-1beta/immunology
- Macrophages/drug effects
- Macrophages/immunology
- Macrophages/pathology
- Pentacyclic Triterpenes
- Rats
- Rats, Wistar
- Synovial Membrane/drug effects
- Synovial Membrane/immunology
- Synovial Membrane/pathology
- Treatment Outcome
- Triterpenes/pharmacology
- Tumor Necrosis Factor-alpha/genetics
- Tumor Necrosis Factor-alpha/immunology
Collapse
Affiliation(s)
- Rita Cascão
- Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal
- * E-mail:
| | - Bruno Vidal
- Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal
| | - Inês P. Lopes
- Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal
| | - Eunice Paisana
- Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal
| | - José Rino
- Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal
| | | | - João E. Fonseca
- Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal
- Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, Lisbon Academic Medical Centre, Lisbon, Portugal
| |
Collapse
|
12
|
Imran MY, Saira Khan EA, Ahmad NM, Farman Raja S, Saeed MA, Ijaz Haider I. Depression in Rheumatoid Arthritis and its relation to disease activity. Pak J Med Sci 2015; 31:393-7. [PMID: 26101498 PMCID: PMC4476349 DOI: 10.12669/pjms.312.6589] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2014] [Revised: 10/09/2014] [Accepted: 12/09/2014] [Indexed: 01/25/2023] Open
Abstract
Objectives: To determine the level of depression in Rheumatoid Arthritis and its relationship with severity of Rheumatoid Arthritis. Methods: This cross sectional analytical study was conducted from March 2014 to May 2014. Total 102 cases of Rheumatoid Arthritis (RA) diagnosed as per ACR (American College of Rheumatology) 1987 criteria were enrolled from Rheumatology Department, Fatima Memorial Hospital. Severity of Rheumatoid Arthritis was assessed by Health Assessment Questionnaire (HAQ) and disease activity score (DAS - 28) while severity of depression was measured by Beck Depression Inventory (BDI) scale II questionnaire. The relationship between depression and disease activity (severity) of Rheumatoid Arthritis was assessed by calculating correlation coefficient between depression, disease activity score (DAS 28) of Rheumatoid Arthritis and health assessment questionnaire (HAQ). Results: Out of 102 patients, 77(75.5%) were females and 25(24.5%) males. The mean age of patients was 43.5± 11.9 years and the mean duration of disease was 7.8 ± 5.5 years.71.5% of Rheumatoid Arthritis patients were found to have some degree of depression and this was directly related to the severity of disease. Moderate and severe depression were present in 23 (22.5%) and 19(18.6%) patients respectively. Conclusion: In this study, almost three-fourths of Rheumatoid Arthritis patients were found to have depression. There was a strong association between Rheumatoid Arthritis disease activity and the level of depression. So it is imperative for clinicians treating Rheumatoid Arthritis patients to screen them for co morbid depression and manage it accordingly.
Collapse
Affiliation(s)
- Muhammad Yaser Imran
- Dr. Muhammad Yaser Imran, FCPS. Department of Rheumatology, Fatima Memorial Hospital, Lahore, Pakistan
| | - Elaine Anwer Saira Khan
- Dr. Saira Elaine Anwer Khan, MRCP. Department of Rheumatology, Fatima Memorial Hospital, Lahore, Pakistan
| | - Nighat Mir Ahmad
- Prof. Dr. Nighat Mir Ahmad, MD, FACP, FACR. Department of Rheumatology, Fatima Memorial Hospital, Lahore, Pakistan
| | - Sumaira Farman Raja
- Dr. Sumaira Farman Raja, MBBS, FRCP, FACP, FACR. Department of Rheumatology, Fatima Memorial Hospital, Lahore, Pakistan
| | - Muhammad Ahmed Saeed
- Dr. Muhammad Ahmed Saeed, FCPS medicine, FCPS Rheumatology. Department of Rheumatology, Fatima Memorial Hospital, Lahore, Pakistan
| | - Imran Ijaz Haider
- Prof. Dr. Imran Ijaz Haider, MRC Psychiatry. Department of Psychiatry. Fatima Memorial Hospital, Lahore, Pakistan
| |
Collapse
|
13
|
Romano E, Terenzi R, Manetti M, Peruzzi F, Fiori G, Nacci F, Bellando-Randone S, Matucci-Cerinic M, Guiducci S. Disease activity improvement in rheumatoid arthritis treated with tumor necrosis factor-α inhibitors correlates with increased soluble Fas levels. J Rheumatol 2014; 41:1961-5. [PMID: 25179850 DOI: 10.3899/jrheum.131544] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
OBJECTIVE Rheumatoid arthritis (RA) is characterized by chronic synovial inflammation and hyperplasia. Tumor necrosis factor-α (TNF-α) plays a pivotal role in RA by interfering with the Fas-Fas ligand (FasL) proapoptotic pathway. We investigated the circulating levels of soluble Fas (sFas) and soluble FasL (sFasL), and their possible correlation with disease activity and improvement after anti-TNF-α treatment in RA. METHODS Serum levels of sFas and sFasL were measured by quantitative ELISA in 52 patients with RA before and after 3 months of anti-TNF-α treatment (adalimumab, n = 32; infliximab, n = 20). Disease activity measures [Disease Activity Score at 28 joints-erythrocyte sedimentation rate (DAS28-ESR), C-reactive protein (CRP)] were recorded before and after treatment. Forty age-matched and sex-matched healthy subjects served as controls. RESULTS No significant differences in serum sFas levels were detected between anti-TNF-α-naive patients with RA and controls. After anti-TNF-α treatment, serum sFas levels significantly increased in patients with RA compared to both anti-TNF-α-naive patients and controls. Increased sFas levels inversely correlated with disease activity variables (DAS28-ESR: r = -0.739, CRP: r = -0.636, both p < 0.001). No significant differences in sFasL levels were detected in patients with RA before and after anti-TNF-α treatment. CONCLUSION In RA, an increase in sFas levels closely correlates with improvement in disease activity induced by TNF-α inhibitors, suggesting their ability to modulate Fas-mediated synoviocyte apoptosis.
Collapse
Affiliation(s)
- Eloisa Romano
- From the Department of Experimental and Clinical Medicine, Section of Internal Medicine; Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi; DENOthe Centre; Department of Experimental and Clinical Medicine, Section of Anatomy and Histology, University of Florence, Florence, Italy.E. Romano, PhD; R. Terenzi, MD; F. Peruzzi, MD; G. Fiori, MD; F. Nacci, MD; S. Bellando-Randone, MD, PhD; M. Matucci-Cerinic, MD, PhD; S. Guiducci, MD, PhD, Department of Experimental and Clinical Medicine, Section of Internal Medicine, Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi; DENOthe Centre; M. Manetti, PhD; Department of Experimental and Clinical Medicine, Section of Anatomy and Histology, University of Florence.
| | - Riccardo Terenzi
- From the Department of Experimental and Clinical Medicine, Section of Internal Medicine; Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi; DENOthe Centre; Department of Experimental and Clinical Medicine, Section of Anatomy and Histology, University of Florence, Florence, Italy.E. Romano, PhD; R. Terenzi, MD; F. Peruzzi, MD; G. Fiori, MD; F. Nacci, MD; S. Bellando-Randone, MD, PhD; M. Matucci-Cerinic, MD, PhD; S. Guiducci, MD, PhD, Department of Experimental and Clinical Medicine, Section of Internal Medicine, Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi; DENOthe Centre; M. Manetti, PhD; Department of Experimental and Clinical Medicine, Section of Anatomy and Histology, University of Florence
| | - Mirko Manetti
- From the Department of Experimental and Clinical Medicine, Section of Internal Medicine; Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi; DENOthe Centre; Department of Experimental and Clinical Medicine, Section of Anatomy and Histology, University of Florence, Florence, Italy.E. Romano, PhD; R. Terenzi, MD; F. Peruzzi, MD; G. Fiori, MD; F. Nacci, MD; S. Bellando-Randone, MD, PhD; M. Matucci-Cerinic, MD, PhD; S. Guiducci, MD, PhD, Department of Experimental and Clinical Medicine, Section of Internal Medicine, Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi; DENOthe Centre; M. Manetti, PhD; Department of Experimental and Clinical Medicine, Section of Anatomy and Histology, University of Florence
| | - Francesca Peruzzi
- From the Department of Experimental and Clinical Medicine, Section of Internal Medicine; Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi; DENOthe Centre; Department of Experimental and Clinical Medicine, Section of Anatomy and Histology, University of Florence, Florence, Italy.E. Romano, PhD; R. Terenzi, MD; F. Peruzzi, MD; G. Fiori, MD; F. Nacci, MD; S. Bellando-Randone, MD, PhD; M. Matucci-Cerinic, MD, PhD; S. Guiducci, MD, PhD, Department of Experimental and Clinical Medicine, Section of Internal Medicine, Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi; DENOthe Centre; M. Manetti, PhD; Department of Experimental and Clinical Medicine, Section of Anatomy and Histology, University of Florence
| | - Ginevra Fiori
- From the Department of Experimental and Clinical Medicine, Section of Internal Medicine; Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi; DENOthe Centre; Department of Experimental and Clinical Medicine, Section of Anatomy and Histology, University of Florence, Florence, Italy.E. Romano, PhD; R. Terenzi, MD; F. Peruzzi, MD; G. Fiori, MD; F. Nacci, MD; S. Bellando-Randone, MD, PhD; M. Matucci-Cerinic, MD, PhD; S. Guiducci, MD, PhD, Department of Experimental and Clinical Medicine, Section of Internal Medicine, Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi; DENOthe Centre; M. Manetti, PhD; Department of Experimental and Clinical Medicine, Section of Anatomy and Histology, University of Florence
| | - Francesca Nacci
- From the Department of Experimental and Clinical Medicine, Section of Internal Medicine; Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi; DENOthe Centre; Department of Experimental and Clinical Medicine, Section of Anatomy and Histology, University of Florence, Florence, Italy.E. Romano, PhD; R. Terenzi, MD; F. Peruzzi, MD; G. Fiori, MD; F. Nacci, MD; S. Bellando-Randone, MD, PhD; M. Matucci-Cerinic, MD, PhD; S. Guiducci, MD, PhD, Department of Experimental and Clinical Medicine, Section of Internal Medicine, Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi; DENOthe Centre; M. Manetti, PhD; Department of Experimental and Clinical Medicine, Section of Anatomy and Histology, University of Florence
| | - Silvia Bellando-Randone
- From the Department of Experimental and Clinical Medicine, Section of Internal Medicine; Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi; DENOthe Centre; Department of Experimental and Clinical Medicine, Section of Anatomy and Histology, University of Florence, Florence, Italy.E. Romano, PhD; R. Terenzi, MD; F. Peruzzi, MD; G. Fiori, MD; F. Nacci, MD; S. Bellando-Randone, MD, PhD; M. Matucci-Cerinic, MD, PhD; S. Guiducci, MD, PhD, Department of Experimental and Clinical Medicine, Section of Internal Medicine, Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi; DENOthe Centre; M. Manetti, PhD; Department of Experimental and Clinical Medicine, Section of Anatomy and Histology, University of Florence
| | - Marco Matucci-Cerinic
- From the Department of Experimental and Clinical Medicine, Section of Internal Medicine; Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi; DENOthe Centre; Department of Experimental and Clinical Medicine, Section of Anatomy and Histology, University of Florence, Florence, Italy.E. Romano, PhD; R. Terenzi, MD; F. Peruzzi, MD; G. Fiori, MD; F. Nacci, MD; S. Bellando-Randone, MD, PhD; M. Matucci-Cerinic, MD, PhD; S. Guiducci, MD, PhD, Department of Experimental and Clinical Medicine, Section of Internal Medicine, Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi; DENOthe Centre; M. Manetti, PhD; Department of Experimental and Clinical Medicine, Section of Anatomy and Histology, University of Florence
| | - Serena Guiducci
- From the Department of Experimental and Clinical Medicine, Section of Internal Medicine; Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi; DENOthe Centre; Department of Experimental and Clinical Medicine, Section of Anatomy and Histology, University of Florence, Florence, Italy.E. Romano, PhD; R. Terenzi, MD; F. Peruzzi, MD; G. Fiori, MD; F. Nacci, MD; S. Bellando-Randone, MD, PhD; M. Matucci-Cerinic, MD, PhD; S. Guiducci, MD, PhD, Department of Experimental and Clinical Medicine, Section of Internal Medicine, Division of Rheumatology, Azienda Ospedaliero-Universitaria Careggi; DENOthe Centre; M. Manetti, PhD; Department of Experimental and Clinical Medicine, Section of Anatomy and Histology, University of Florence
| |
Collapse
|
14
|
Myelosuppressive and hepatotoxic potential of leflunomide and methotrexate combination in a rat model of rheumatoid arthritis. Pharmacol Rep 2014; 67:102-14. [PMID: 25560583 DOI: 10.1016/j.pharep.2014.08.009] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2013] [Revised: 07/09/2014] [Accepted: 08/01/2014] [Indexed: 11/20/2022]
Abstract
BACKGROUND Safety of the combination of leflunomide and methotrexate was examined in several studies with inconclusive results. The present study was designed to compare the efficacy and safety of the combination of leflunomide and methotrexate in adjuvant-induced arthritis (AIA) in rats focusing on immunosuppressive and hepatotoxic effects. METHODS Eighty four rats were divided into seven groups. Group 1: Sham control, group 2: the vehicle control, group 3: methotrexate group, group 4-5: leflunomide (5 and 10mg/kg/day) groups, group 6-7: combination 1 and 2 [methotrexate+leflunomide (5 and 10mg/kg/day)] groups, respectively. RESULTS The current results indicated that combination therapies improved the ankle circumference and clinical scores compared to monotherapies; histopathological examination confirmed these findings. The myelosuppressive effect of leflunomide (10mg/kg/day) was comparable to that produced by methotrexate as indicated by the complete blood count and bone marrow cellularity; however their combination resulted in greater toxicity. Furthermore, methotrexate greatly affected the splenic histopathology compared to leflunomide and the combination therapy produced a greater effect compared to leflunomide not methotrexate. Differently, assessment of the hepatotoxic potential of the two drugs highlighted that leflunomide induced a dose-dependent increase in the fibrosis score which was higher in their magnitude than that induced by methotrexate. Leflunomide (10mg/kg/day) and combination 2 groups showed the greatest degree of liver fibrosis. CONCLUSIONS In rats with AIA, current drug combinations provided higher therapeutic benefit compared to monotherapies, however, greater toxicities were observed. Therefore, continuous monitoring of hematologic parameters and liver function will be recommended in clinical settings.
Collapse
|
15
|
Chang JH, Lee KJ, Kim SK, Yoo DH, Kang TY. Validity of SW982 synovial cell line for studying the drugs against rheumatoid arthritis in fluvastatin-induced apoptosis signaling model. Indian J Med Res 2014; 139:117-24. [PMID: 24604047 PMCID: PMC3994728] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
BACKGROUND & OBJECTIVES To study effects of drugs against rheumatoid arthritis (RA) synoviocytes or fibroblast like synoviocytes (FLS) are used. To overcome the drawbacks of using FLS, this study was conducted to show the validity of SW982 synovial cell line in RA study. METHODS 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, Annexin V propidium iodide (PI) staining, mitochondrial membrane potential assay, Triton X-114 Phase partitioning, and immunolot for apoptosis signaling in SW982 human synovial cell line were performed. RESULTS Fluvastatin induced apoptosis in a dose- and time-dependent manner in TNFα -stimulated SW982 human synovial cells. A geranylgeranylpyrophosphate (GGPP) inhibitor, but not a farnesylpyrophosphate (FPP) inhibitor, induced apoptosis, and fluvastatin-induced apoptosis was associated with the translocation of isoprenylated RhoA and Rac1 proteins from the cell membrane to the cytosol. Fluvastatin-induced downstream apoptotic signals were associated with inhibition of the phosphoinositide 3-kinase (PI3K)/Akt pathway. Accordingly, 89 kDa apoptotic cleavage fragment of poly (ADP-ribose) polymerase (PARP) was detected. INTERPRETATION & CONCLUSIONS Collectively, our data indicate that fluvastatin induces apoptotic cell death in TNFα-stimulated SW982 human synovial cells through the inactivation of the geranylgerenylated membrane fraction of RhoA and Rac1 proteins and the subsequent inhibition of the PI3K/Akt signaling pathway. This finding shows the validity of SW982 cell line for RA study.
Collapse
Affiliation(s)
- Jae-Ho Chang
- Institute of Biomaterials, Yonsei University, Wonju, Korea
| | - Kyu-Jae Lee
- Department of Environmental Medical Biology, Yonsei University Wonju College of Medicine, Wonju, Korea
| | - Soo-Ki Kim
- Institute of Biomaterials, Yonsei University, Wonju, Korea,Department of Microbiology, Yonsei University Wonju College of Medicine, Wonju, Korea,Reprint requests: Dr Soo-Ki Kim, Department of Microbiology, Wonju College of Medicine Yonsei University 162 Ilsan-dong, Wonju, Gangwon province 220-701, Republic of Korea e-mail: and
Dr Tae-Young Kang, Department of Rheumatology, Yonsei University Wonju College of Medicine Wonju, Gangwon province 220-701, Republic of Korea e-mail:
| | - Dae-Hyun Yoo
- The Hospital for Rheumatic Diseases, Hanyang University Medical Center, Seoul, Korea
| | - Tae-Young Kang
- Department of Rheumatology, Yonsei University Wonju College of Medicine, Wonju, Korea,Reprint requests: Dr Soo-Ki Kim, Department of Microbiology, Wonju College of Medicine Yonsei University 162 Ilsan-dong, Wonju, Gangwon province 220-701, Republic of Korea e-mail: and
Dr Tae-Young Kang, Department of Rheumatology, Yonsei University Wonju College of Medicine Wonju, Gangwon province 220-701, Republic of Korea e-mail:
| |
Collapse
|